FIELD: biotechnology.
SUBSTANCE: immunogen containing a glycoengineered coronavirus spike protein containing a plurality of truncated N-glycans and one or more unmodified O-glycans is described, wherein the glycoengineered coronavirus spike protein consists of the amino acid sequence SEQ ID NO: 1 or a variant thereof having at least 96% identity with the amino acid sequence of SEQ ID NO: 1, or an immunologically active fragment thereof. The following is proposed: an immunogenic composition for inducing an immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a variant thereof in a subject in need thereof, containing an effective amount of the immunogen described. The following is disclosed: a method of inducing an immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a variant thereof in a subject in need thereof, comprising administering to the subject an effective amount of the proposed immunogenic composition.
EFFECT: invention provides improved immunogens, vaccines and methods of more effectively preventing and treating novel coronavirus infections.
20 cl, 13 dwg, 22 ex
Title | Year | Author | Number |
---|---|---|---|
AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
METHOD FOR CREATING LIVE STRAIN OF ENTEROCOCCUS L3-SARS BASED ON BIOLOGICALLY ACTIVE STRAIN OF E. FAECIUM L3 | 2021 |
|
RU2782529C1 |
POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
Authors
Dates
2024-03-26—Published
2022-04-12—Filed